Effectiveness of pindolol plus serotonin uptake inhibitors in depression: A meta-analysis of early and late outcomes from randomised controlled trials

Journal of Affective Disorders

Volumn 79, Issue 1-3, 2004, Pages 137-147

  Ballesteros, Javier ^a,b   Callado, Luis F ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Institute of Psychiatric Research   (Spain)

Author keywords

Depression; Effectiveness; Meta analysis; Outcome; Pindolol; SSRI

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PINDOLOL; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG TOLERABILITY; HEADACHE; HUMAN; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VOMITING;

EID: 1542404781     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(02)00404-4     Document Type: Article

References (53)

1. Altman D.G. Confidence intervals for the number needed to treat. Br. Med. J. 317:1998;1309-1312.
2. Artigas F. Limitations to enhancing the speed of onset of antidepressants. Are rapid action antidepressants possible? Hum. Psychopharmacol. Clin. Exp. 16:2001;29-36.
3. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22:2001;224-228.
4. Artigas F., Pérez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
5. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19:1996;378-383.
6. Ballenger J.C. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry. 60:(Suppl. 22):1999;29-34.
7. Bel N., Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur. J. Pharmacol. 229:1992;101-103.
8. Berman R.M., Anand A., Cappiello A., Miller H.L., Hu X.S., Oren D.A., Charney D.S. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry. 45:1999;1170-1177.
9. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
10. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
11. Blier P., Bergeron R. The use of pindolol to potentiate antidepressant medication. J. Clin. Psychiatry. 59:(Suppl. 5):1998;16-23.
12. Blier P., Bergeron R., de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 16:1997;333-338.
13. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
14. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am. J. Psychiatry. 155:1998;1346-1351.
15. Bradburn M.J., Deeks J.J., Altman D.G. Metan - an alternative meta-analysis command. Stata Tech. Bull. 44:1998;4-15.
16. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 333:1986;342-348.
17. Corkeron M.A. Serotonin syndrome - a potentially fatal complication of antidepressant therapy. Med. J. Aust. 163:1995;481-482.
18. de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J. Clin. Psychiatry. 51:(Suppl. B):1990;4-8.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 7:1986;177-188.
20. Fleiss J.L. The statistical basis of meta-analysis. Stat. Methods Med. Res. 2:1993;121-145.
21. Gilbody S.M., Song F., Eastwood A.J., Sutton A. The causes, consequences and detection of publication bias in psychiatry. Acta Psychiatr. Scand. 102:2000;241-249.
22. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6:1967;278-296.
24. Hedges L.V., Olkin I. Statistical Methods for Meta-Analysis. 1985;Academic Press, Inc, San Diego, CA.
25. Invernizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584:1992;322-324.
26. Kinney G.G., Taber M.T., Gribkoff V.K. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol. Neurobiol. 21:2000;137-152.
27. Lauge N., Behnke K., Søgaard J., Bahr B., Bech P. Responsiveness of observer rating scales by analysis of number of days until improvement in patients with major depression. Eur. Psychiatry. 13:1998;143-145.
28. Leonard B.E. Pharmacology of new antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:1984;97-108.
29. Maes M., Libbrecht I., van Hunsel F., Campens D., Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19:1999;177-182.
30. Maes M., Vandoolaeghe E., Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J. Affect. Disord. 41:1996;201-210.
31. McAskill R., Mir S., Taylor D. Pindolol augmentation of antidepressant therapy. Br. J. Psychiatry. 173:1998;203-208.
32. McQuay H.J., Moore A. Using numerical results from systematic reviews in clinical practice. Ann. Intern. Med. 126:1997;712-720.
33. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
34. Montgomery S.A. New developments in the treatment of depression. J. Clin. Psychiatry. 60:1999;10-15.
35. Moreno F.A., Gelenberg A.J., Bachar K., Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry. 58:1997;437-439.
36. Oakes M. The logic and role of meta-analysis in clinical research. Stat. Method. Med. Res. 2:1993;147-160.
37. Olver J.S., Cryan J.F., Burrows G.D., Norman T.R. Pindolol augmentation of antidepressants: a review and rationale. Aust. N.Z. J. Psychiatry. 34:2000;71-79.
38. Pérez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
39. Pérez V., Puigdemont D., Gilaberte I., Alvarez E., Artigas F. Augmentation of fluoxetine antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J. Clin. Psychopharmacol. 21:2001;36-45.
40. Pérez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry. 56:1999;375-379.
41. Prien R.F., Carpenter L.L., Kupfer D.J. The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. Arch. Gen. Psychiatry. 48:1991;796-800.
42. Puzantian T., Kawase K. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Pharmacotherapy. 19:1999;205-212.
43. Rosenthal R. The 'file drawer problem' and tolerance for null results. Psychol. Bull. 86:1979;638-641.
44. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry. 3:1998;508-511.
45. Smith T.C., Spiegelhalter D.J., Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat. Med. 14:1995;2685-2699.
46. Spiegelhalter, D.J., Thomas, A., Best, N.G., 2000. WinBUGS Version 1.2. User Manual. Cambridge, MRC Biostatistics Unit.
47. StataCorp, 2001. Stata Statistical Software: Release 7.0. Stata Corporation, College Station, TX.
48. Sugrue M.F. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol. Ther. 21:1983;1-33.
49. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81-89.
50. Thase M.E. Methodology to measure onset of action. J. Clin. Psychiatry. 62:(Suppl. 15):2001;18-21.
51. Yatham L.N., Lint D., Lam R.W., Zis A.P. Adverse effects of pindolol augmentation in patients with bipolar depression. J. Clin. Psychopharmacol. 19:1999;383-384.
52. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446-450.
53. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J. Clin. Psychopharmacol. 18:1998;441-446.